Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer. Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase 1B study.

From http://besthealthnews.com/2019/09/investigational-drug-with-immunotherapy-may-provide-new-therapeutic-opportunity-for-patients-previously-treated-for-kidney-and-lung-cancer/?utm_source=rss&utm_medium=rss&utm_campaign=investigational-drug-with-immunotherapy-may-provide-new-therapeutic-opportunity-for-patients-previously-treated-for-kidney-and-lung-cancer

from
https://healthnews010.wordpress.com/2019/09/26/investigational-drug-with-immunotherapy-may-provide-new-therapeutic-opportunity-for-patients-previously-treated-for-kidney-and-lung-cancer/

From https://aubreyflores.blogspot.com/2019/09/investigational-drug-with-immunotherapy.html

from
https://aubreyflores.wordpress.com/2019/09/26/investigational-drug-with-immunotherapy-may-provide-new-therapeutic-opportunity-for-patients-previously-treated-for-kidney-and-lung-cancer/